Stryker stock: Piper Sandler raises target after surgeon survey

Published on 11/13/2026 at 17:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Piper Sandler raised its target after a survey found recent orthopedic weakness. The firm still expects mid-single-digit procedure growth through 2026 and 2027.

Analyst view meets orthopedic weakness

Piper Sandler kept its Overweight rating while pointing to recent pressure in orthopedic procedures.
The survey linked part of the weakness to greater patient affordability challenges.
Expected procedure growth offers a more constructive medium-term view for investors.

Stryker Corp., US8636671013, Illustration mit AI erstellt.

Piper Sandler raised its price target for Stryker on November 9, according to Markets Insider. Analyst Matt O'Brien lifted the target to 350 US dollars from 325 US dollars and kept an Overweight rating on the medical-device maker.

The view followed a survey of 26 hip and knee surgeons after relatively soft third-quarter orthopedic results. The responses pointed to weakness in recent months, with some physicians reporting greater patient affordability challenges. Piper Sandler identified affordability as a likely contributor to the slowdown.

Procedure growth remains the counterpoint

Despite the softer market signals, Piper Sandler expects procedure volumes to grow at a mid-single-digit rate through the end of 2026 and in 2027. That outlook suggests the firm sees the recent pressure as temporary rather than structural, although the survey leaves demand and execution as important variables for investors.

Stryker stock traded at 284.45 euros on Lang & Schwarz at 17:14 CET on Friday, November 13, 2026, 0.53 percent above the Xetra close of Thursday, November 12, at 282.95 euros. The analyst view therefore arrives as investors weigh near-term orthopedic softness against expectations for a recovery in procedure volumes.